

## PERFORMANCE IN DELIVERING CLINICAL RESEARCH (Q3, 2015/16)

Research Ethics Committee Reference Number	Name of Trial	Target number of patients	Date agreed to recruit target number of patients	Trial status	Target met within the agreed time?	Comments
12/NW/0251	A multicentre, stratified, open, randomized, comparator-controlled, parallelgroup phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut	3	01/06/2015	Closed - Follow Up Complete	Y	Study recruited to time and target.
10/H0801/67	Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Risk Prostate Cancer: Feasibility Study	15	17/07/2016	Suspended	N/A	Date agreed to recruit to target not yet passed.
13/NW/0363	A Multicenter Openlabel Extension (OLE) Study to Assess the Long term Safety and Efficacy of AMG 145	8	01/01/2014	Closed - Follow Up Complete	N	2 patients recruited.
13/NW/0583	A 24-Week International, Multi-center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adult Subjects with Type 2 Diabetes who have Inadequate GI	1	31/12/2016	Open	N/A	Date agreed to recruit to target not yet passed.
12/SW/0378	Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)	6	02/02/2015	Closed - In Follow Up	N	Bereavement in study team - after discussion with the Sponsor, we agreed to postpone start of recruitment. First patient consented in September 2014; there were 5 patients recruited in total.
13/NI/0188	A singlearm trial to evaluate the effectiveness of PCI of de novo 3vessel disease applying the SYNTAX score II with pressure wire functional assessment and IVUS guidance, using an everolimuseluting stent with biodegradable abluminal coating	17	31/12/2019	Open	Y	Study recruited to time and target.
12/LO/1320	Aneurysm Treatment using the HeliFX Aortic Securement System Global Registry	5	26/11/2013	Closed - Follow Up Complete	N	Target of 5 patients reached within 14 months; contract stated 12 months. Total of 8 patients recruited.
13/WS/0282	Prospective, single-arm, global multi-center study to evaluate treatment of obstructive superficial femoral artery and/or popliteal lesions with a novel paclitaxel coated percutaneous angioplasty balloon.	10	01/01/2016	Closed - In Follow Up	Y	Study recruited to time and target.
13/EE/0444	Maximizing CRT Delivery by using Multipolar Coronary Sinus Lead Acuity x4	20	31/12/2014	Open	N	12 patients recruited into the study. Team continues to try to identify new patients.
14/LO/0362	Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel-group, 24-week study to assess the efficacy, safety and tolerability of macitentan in subjects with inoperable chronic thromboembolic pulmonary hypertension	3	28/07/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/NW/0002	Prospective, randomised, controlled investigation comparing the safety and performance of 032-11 Surgical Haemostat 2g Applicator with FLOSEAL Hemostatic Matrix as an adjunctive haemostat in cardiac surgery and thoracic aortic surgery -VICTORY Study	20	31/07/2015	Open	N	Study recruited 45 patients.
14/LO1370	Macitentan in the treatment of Inoperable chronic Thromboembolic pulmonary hypertension (Open-Label)	1	30/11/2016	Open	N/A	Date agreed to recruit to target not yet passed.
12/YH/0504	Assessment of the efficacy and safety of a new wound dressing in the local treatment of diabetic foot ulcers: A Prospective, randomised, controlled, doubleblind, European multicentre clinical trial.	4	29/11/2016	Open	N/A	Date agreed to recruit to target not yet passed.
14/LO/2143	Measurement of low-energy stimulation in patients with atrial fibrillation	15	30/06/2016	Open	N/A	Date agreed to recruit to target not yet passed.
15/EM/0021	A randomised, double blind, placebo controlled multicenter trial, examining the effect of Natrox? on the rates of healing for chronic diabetic foot ulcers	5	06/05/2016	Open	N/A	Date agreed to recruit to target not yet passed.

14/SC/0032	PHASE 3 MULTI CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF 04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS			Open	N/A	No target/date agreed with sponsor. Study recruited 3 patients.
14/SC/0033	PHASE 3 MULTI CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF 04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS			Open	N/A	No target/date agreed with sponsor. Study recruited 2 patients.
15/LO/0140	CLEANER Assessment of efficacy and safety for a new wound dressing URGO 310 3166 in the local treatment of venous or mixed leg ulcers: a European, randomised clinical trial.	4	31/08/2016	Open	N/A	Date agreed to recruit to target not yet passed.
14/NE/1109	Cardiac Resynchronization Therapy Efficacy Enhancements (CRTEE)	5	01/01/2017	Open	N/A	Date agreed to recruit to target not yet passed.
15/WS/0147	A Multicenter, Open Label, Prospective, Post Approval Study of the INCRAFT® AAA Stent Graft System in Subjects with Abdominal Aortic Aneurysms	24	30/06/2021	Open	N/A	Date agreed to recruit to target not yet passed.
12/LO/1823	A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Infected	10	19/12/2013	Closed - In Follow Up	N	2 patients recruited.
13/EE/0199	An Exploratory Study of the Safety and Efficacy of BOTOX for the Treatment of Premature Ejaculation	10	01/08/2015	Open	N	Entry criteria for this study are very strict. Sponsor had to advertise study to the public as all 4 UK sites and 8 USA sites were having difficulties meeting recruitment target. There were 7/10 patients recruited at our site by the agreed target date.
14/LO/1381	A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily versus Raltegravir 400 mg Twice Daily, Each in Combination with TRUVADA	5	30/04/2015	Closed - In Follow Up	N	Study closed to recruitment by sponsor before agreed date to recruit by.
15/LO/0652	A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 Infected Adults	5	31/08/2017	Open	N/A	Date agreed to recruit to target not yet passed.
15/LO/1163	A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed on Regimens containing ABC/3TC			Open	N/A	
15/LO/0881	A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naive HIV-1 Infected Subjects			Open	N/A	
14/LO/0102	A First Time in Human, Double Blind, Randomised, Placebo Controlled Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Intravenous Doses of SNF472 in Healthy Male Volunteers	8		Open	N/A	No date agreed with sponsor. Study recruited 3 patients to date.
14/LO/0865	A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy	5		Open	N/A	No date agreed with sponsor. Study recruited 2 patients to date.
14/NW/0008	Golimumab: A Phase 4, UK Open Label, Single arm Study on its Utilization and Impact in Ulcerative Colitis	6	31/03/2016	Closed - In Follow Up	N	Study closed to recruitment by sponsor before agreed date to recruit by.
14/WM/1262	An Open Label Study of Sofosbuvir/GS5816 FixedDose Combination in Subjects with Chronic HCV Infection	1		Open	N/A	No date agreed with sponsor. Study recruited 2 patients to date.
15/LO/0743	A phase I, randomised, double-blind, placebo-controlled, multicentre, ascending-dose trial to evaluate safety, tolerability and immunogenicity of Vaccine FP-02.2 in HBeAg-negative hepatitis B patients as an add-on treatment to entecavir or tenofovir			Open	N/A	No target/date agreed.

15/LO/1228	An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir with or without Dasabuvir in Adults with Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, with Severe Renal Impairment (?) (RUBY-II)	4		Open	N/A	Study recruited 4 patients to date.
15/NW/0700	M13-583 A Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)	3	31/03/2016	Open	N/A	Date agreed to recruit to target not yet passed.
15/NW/0871	A Single-Arm, Open-Label, Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally-Impaired Adults with Chronic Hepatitis C Virus Genotype 1 – 6 Infection (EXPEDITION-4)	4	31/03/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/SC/0383	A Two Part, Randomized Clinical Trial to Study Biomarkers of MK8237 (SCH 900237) Treatment in Subjects with House Dust Mite Induced Allergic Rhinitis or Rhinconjunctivitis	20	31/01/2015	Closed - In Follow Up	Y	Study recruited to time and target.
14/NE/1072	A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED BRONCHOSCOPY STUDY TO EVALUATE THE EFFECTS OF LEBRIKIZUMAB ON AIRWAY EOSINOPHILIC INFLAMMATION IN PATIENTS WITH UNCONTROLLED ASTHMA ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER MEDICATION	4	31/03/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/SC/0092	A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis (Protocol No: CBAF312A230	6	30/04/2014	Closed - In Follow Up	N	Sponsor delays with IMP supply. Target of 6 reached in following month. Total of 7 patients recruited.
12/SC/0538	A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD)	6	01/01/2014	Closed - In Follow Up	N	Target reached in December 2014.
14/SC/0037	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICIACY AND SAFETY STUDY OF GANTENERUMAB IN SUBJECTS WITH MILD ALZHEIMER'S DISEASE	6	31/01/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1758	A Phase III, Randomized, PlaceboControlled, ParallelGroup, DoubleBlind Clinical Trial to Study the Efficacy and Safety of MK8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD).	10		Open	N/A	No date agreed. Study recruited 9/10 patients to date.
14/SC/0038	PET IMAGING SUBSTUDY ASSOCIATED WITH: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICIACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH MILD ALZHEIMER'S DISEASE	5	31/01/2016	Open	N/A	Date agreed to recruit to target not yet passed.
14/NW/0290	Registry of Deep Brain Stimulation with the VERCISE? System: Vercise DBS Registry	10		Open	N/A	No date agreed with sponsor. Study recruited 4 patients to date.
14/YH/1153	An Open-Label, Extension Study of the Effects of Leuco-methylthioninium bi (hydromethanesulfonate) in Subjects with Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia	10		Open	Y	Study recruited to time and target.
14/NW/1427	A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinsons Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control	4	13/12/2017	Open	N/A	Date agreed to recruit to target not yet passed.
14/LO/1994	The AMARANTH study - A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease	20	01/10/2016	Open	N/A	Date agreed to recruit to target not yet passed.
14/WS/1105	REVEAL 101MS408 Multicenter study of Natalizumab v Fingolimod in MS	20	25/01/2016	Closed - Follow Up Complete	N	Sponsor closed recruitment early.
15/SC/0165	A Single-Blinded, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL? Fibrin Sealant (Human) Compared to a Hydrogel Sealant as an Adjunct to Sutured Dural Repair	20		Open	N/A	No date agreed with sponsor. Study recruited 3 patients to date.
14/WS/1146	Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism (...) (ESUS) aspirin 100 mg - NAVIGATE ESUS	20	31/12/2016	Open	N/A	Date agreed to recruit to target not yet passed.

11/LO/0537	A Multicenter, randomized, double-blind, placebo-controlled Study of the Efficacy of Natalizumab or Reducing Disability Progression in Subjects with Secondary Progressive Multiple Sclerosis	20	29/03/2013	Closed - Follow Up Complete	Y	Study recruited to time and target.
10/H0605/59	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease (WN25203)	6	01/09/2013	Closed - In Follow Up	Y	Study recruited to time and target.
10/H0605/58	Sub Study to study WN25203,using positron emission tomography (PET) with an amyloid tracer to assess changes in amyloid load over time in subjects with Prodromal Alzheimer's Disease	1	30/09/2012	Closed - In Follow Up	Y	Study recruited to time and target.
12/NW/0711	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leuco-methylthionium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease (TRx-237-015)	10	01/01/2014	Closed - Follow Up Complete	Y	Study recruited to time and target.
13/LO/1302	A Phase IIb randomised, openlabel study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV1 infected antiretroviral therapy naive women.	4	01/08/2014	Closed - In Follow Up	Y	Study recruited to time and target.
13/LO/0671	A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301	7	28/02/2014	Closed - In Follow Up	Y	Study recruited to time and target.
13/EE/0214	A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial	1	30/09/2018	Open	Y	Study recruited to time and target.
14/LO/0665	A Phase III OpenLabel Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK5172/ MK8742 in TreatmentNa?ve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are on Opiate Substitution Therapy.	4		Closed - In Follow Up	Y	Study recruited to time and target.
14/WM/1056	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV	6		Closed - Follow Up Complete	Y	Study recruited to time and target.
14/YH/1057	A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects with Chronic Genotype 3 HCV Infection	9		Closed - Follow Up Complete	Y	Study recruited to time and target.
09/H0405/51	A Phase II Study of Dasatinib therapy in children & adolescents with PH+ leukaemia with resistance or intolerance to Imatinib.			Closed - In Follow Up	N/A	No target/date agreed with sponsor.
10/H0715/57	A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy	5	01/11/2011	Closed - In Follow Up	Y	Study recruited to time and target.
12/LO/1981	A Randomized, Multicenter, Open-Label Phase III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine Versus Trastuzumab As Adjuvant Therapy For Patients With Her2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologic	3	01/03/2016	Open	Y	Study recruited to time and target.
11/LO/1369	A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy	1	31/08/2014	Closed - In Follow Up	Y	Study recruited to time and target.
13/LO/0855	A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphoma	4		Open	N/A	No date agreed. Study still recruiting.
13/SC/0348	A randomized, OpenLabel, Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib	3	01/10/2014	Closed - Follow Up Complete	Y	Study recruited to time and target.

12/SS/0007	A randomised Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy	4	30/01/2014	Closed - In Follow Up	N	Rare disease study. 2 patients recruited.
13/LO/1352	A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILURE	2	31/03/2014	Closed - In Follow Up	Y	Study recruited to time and target.
13/LO/1081	A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer	1	31/12/2018	Open	N/A	Date agreed to recruit to target not yet passed.
13/NW/0697	PISARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246	4	14/02/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1121	A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First Line Treatment in Metastatic Non Small Cell Lung Cancer Patients with Activating EGFR Mutations Who Have Disease Control after an 8 Week Lead In Tre	4	01/03/2015	Closed - In Follow Up	Y	Study recruited to time and target.
13/LO/1332	A TwoPart Phase 1/2a, OpenLabel, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB111001 in Patients with Advanced Cancers that are Poorly Responsive to Standard Anticancer Treatment	30		Open	N/A	No date agreed. Study still recruiting.
11/LO/0551	A phase I Open-Label Dose Escalation Study of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Subjects with Solid tumors	10	31/12/2015	Open	Y	Study recruited to time and target.
11/LO/0449	A multicenter, global, randomized, double-blind study of axitinib versus placebo in patients with advanced hepatocellular carcinoma following failure of one prior antiangiogenic therapy	2	30/06/2012	Closed - In Follow Up	Y	Study recruited to time and target.
10/H0406/27	Randomised, Multicentre, Open-label, Phase III Study of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma	6		Closed - In Follow Up	N/A	No date agreed. Study still recruiting.
13/WA/0328	Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer	2	31/07/2015	Open	Y	Study recruited to time and target.
07/H1102/84	Sunitinib treatment of renal adjuvant cancer (S-TRAC) A randomised double blind phase 3 study of adjuvant vs placebo in subjects at high risk of recurrent RCC. Study Number: A6181109	3		Closed - In Follow Up	N/A	No date agreed. Study still recruiting.
13/NW/0634	A Phase 1b, multicenter, openlabel, dose escalation study of GSK2256098 (FAK inhibitor) in combination with Trametinib (MEK inhibitor) in subjects with advanced solid tumors	5	30/06/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/EM/0349	A Randomized Phase II Study of Fulvestrant in Combination with the dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen Receptor-Positive Advanced or Metastatic Breast Cancer.	2	27/04/2018	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1557	A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving Deep Subcu	5	31/08/2016	Open	N/A	Date agreed to recruit to target not yet passed.
14/LO/0882	A PHASE III, OPEN-LABEL, MULTICENTER,RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY	4	01/06/2015	Closed - In Follow Up	Y	Study recruited to time and target.
13/EE/0364	A Randomized, Doubleblind, Multicenter Phase 2 Trial of Denosumab in Combination with Chemotherapy as Firstline Treatment of Metastatic Nonsmall Cell Lung Cancer.	12	31/05/2015	Closed - In Follow Up	Y	Study recruited to time and target.
12/LO/1966	A Phase 3, Randomized, Placebocontrolled, Parallelgroup, Multicenter, Doubleblind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Refractory to Somatostatin Analog (SSA) Therapy	1	31/12/2014	Closed - In Follow Up	Y	Study recruited to time and target.

13/SC/0559	A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome	2	31/03/2015	Closed - Follow Up Complete	N	This is a rare disease study with very few suitable patients; also several patients declined to take part.
13/LO/1682	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian,	5	31/12/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/EM/0460	A RANDOMIZED, MULTICENTER, OPEN-LABEL TRIAL COMPARING CHEMOTHERAPY PLUS TRASTUZUMAB PLUS PERTUZUMAB VERSUS CHEMOTHERAPY PLUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2 POSITIVE PRIMARY BREAST CANCER	6	28/02/2016	Closed - In Follow Up	N	Study closed to recruitment nationally early by the sponsored (closed 22/05/2015). This was due to newly available data from the phase III MARIANNE study.
14/NW/0156	OlympiAD - Olaparib monotherapy V Physicians choice chemotherapy	1	31/10/2015	Open	N	This is a rare patient group (less than 1 in 2000). We continue to screen every day and are confident we would capture any eligible patients.
13/LO/0150	A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib	4	23/11/2016	Open	N/A	Date agreed to recruit to target not yet passed.
14/SW/0091	Randomized, DoubleBlind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous NonSmall Cell Lung Cancer (NSCLC)	6	31/03/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/0326	A RANDOMIZED, PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMA	2	30/09/2016	Open	N/A	Date agreed to recruit to target not yet passed.
14/YH/1234	A phase III, doubleblind, randomised study to assess the efficacy and safety of AZD9291 versus a standard of care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as firstline treatment in patients with (...) NonSmall Cell Lung Cancer	2	28/02/2016	Open	N/A	Date agreed to recruit to target not yet passed.
14/NE/1214	A Randomized, Open-Label, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy (?) or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (...)	4		Open	N/A	No date agreed. Study still recruiting.
14/SC/1014	A Randomized, DoubleBlind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas (The JANUS 1 study)	2	26/01/2016	Open	N/A	Date agreed to recruit to target not yet passed.
15/LO/0691	An Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) Monotherapy in Subjects with Advanced or Metastatic (Sq) (NSCLC) who Have Received at Least Two Prior Systemic Regimens for the Treatment of Stage IIIb/IV SqNSCLC	4	15/04/2016	Open	N/A	No date agreed. Study still recruiting.
14/WM/1055	A prospective, multicenter, randomized, double blind, placebocontrolled, 2parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI to placebo in combination with FOLFIRI	5	01/09/2017	Open	N/A	Date agreed to recruit to target not yet passed.
14/LO/1728	A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination with Topotecan (Hycamtin?) in Patients with Solid Tumors	2	28/02/2017	Open	N/A	Date agreed to recruit to target not yet passed.
15/LO/0273	A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus (...) Early Stage TNBC	2		Open	N/A	No date agreed. Study still recruiting.
13/LO/1227	A Multicenter, Randomized, DoubleBlind, PlaceboControlled, Phase III Study of ARN509 in Men with NonMetastatic (M0) CastrationResistant Prostate Cancer	5	30/11/2018	Open	N/A	Date agreed to recruit to target not yet passed.
14/EM/1314	Randomized, Blinded, Multicenter, Phase 2 Study Comparing Veliparib Plus FOLFIRI ? Bevacizumab Versus Placebo Plus FOLFIRI ? Bevacizumab in Previously Untreated Metastatic Colorectal Cancer	3	31/03/2017	Closed - Follow Up Complete	N	Global target met much quicker than Sponsors were anticipating - ICHT only actively recruiting for 1 month. Early closure not communicated.

14/EM/1286	A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer	5	30/11/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1618	A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)			Open	N/A	No target/date agreed with sponsor. Study recruited 1 patient to date.
15/SC/0359	M13-694: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade (?)	6	01/01/2019	Open	N/A	Date agreed to recruit to target not yet passed.
15/SC/0003	An Open-Label, Multicenter, Phase 1/2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B cell Lymphomas	3	31/05/2017	Open	N/A	Date agreed to recruit to target not yet passed.
15/LO/0016	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative (?)	3		Closed - Follow Up Complete	N	Sponsor delays in the lab kit being shipped to site which postponed activation. One patient eligible but declined to take part. Furthermore, recruitment closed early nationally as Sponsor achieved their global target sooner than anticipated.
11/NW/0298	A multicenter, phase III, open-label, randomized study in previously untreated patients with advanced indolent non Hodgkins Lymphoma comparing GA101 (RO5072759) plus chemotherapy with rituximab plus chemotherapy followed by GA101 or rituximab mainten	2	20/12/2013	Closed - In Follow Up	Y	Study recruited to time and target.
12/YH/0318	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia	5	02/07/2014	Closed - Follow Up Complete	Y	Study recruited to time and target.
13/SC/0259	A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas. Gilead GS-US-313-0125	3	31/10/2014	Closed - In Follow Up	Y	Study recruited to time and target.
13/SC/0311	A randomized, controlled, doubleblind  Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013  plus cyclophosphamide, vincristine, prednisone vs. MabThera? plus cyclophosphamide, vincristine, prednisone,  followed by GP2013 o	3	31/12/2014	Closed - Follow Up Complete	N	Study recruited one subject. Not as many eligible patients as expected during the relatively short recruitment window (the study recruited much faster than anticipated and closed sooner).
13/EE/0429	A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies.	6		Open	N/A	No date agreed with sponsor. Study recruited 3 patients to date.
10/H0717/68	A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212/Inactivated Varicella-Zoster Virus (VZV) Vaccine in Recipients of Autologous Hematopoietic	3	25/04/2013	Closed - Follow Up Complete	Y	Study recruited to time and target.
07/Q1206/53	Clinical Trial Protocol CAMN107A2303 - A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CM)	5	15/06/2008	Closed - In Follow Up	Y	Study recruited to time and target.
14/SC/0178	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia	2	31/08/2016	Closed - Follow Up Complete	Y	Study recruited to time and target.
14/YH/0123	An Expanded Access Protocol for Idelalisib (GS-1101) in Combination with Rituximab for Relapsed, Previously Treated Subjects with Chronic Lymphocytic Leukemia.	2	30/04/2016	Closed - Follow Up Complete	Y	Study recruited to time and target.
14/LO/1053	A Phase 3 Randomised double blind Active study Evaluating Memelotinib vs Ruxolitinib in subjects with primary Myelofibrosis (PMF) or Post-poly cythemia Vera or Post-essential Thrombocythemia Myelofibrosis ( Post-PV/ET MF)	2	01/12/2017	Open	N/A	Date agreed to recruit to target not yet passed.

14/LO/0521	A prospective, randomized, open label, two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia positive CML after two different durations of consolidation treatment with nilotinib 300mg BID.	1	01/12/2019	Closed - In Follow Up	Y	Study recruited to time and target.
14/LO/0717	A Multicenter Phase 3 Randomized Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukaemia.	2	12/05/2020	Closed - In Follow Up	Y	Study recruited to time and target.
14/LO/0673	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia.	7	31/03/2018	Open	N/A	Date agreed to recruit to target not yet passed.
14/EM/0186	A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	2	14/08/2018	Open	N/A	Date agreed to recruit to target not yet passed.
14/EM/0130	A Phase 3, Open-Label, Randomized Study of Quizartinib (AC220) Monotherapy vs. Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory to, or Relapsed after, First-Line Treatment	2	30/06/2016	Open	N/A	Date agreed to recruit to target not yet passed.
14/WM/0170	A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis,	2	01/10/2020	Open	Y	Study recruited to time and target.
14/EM/1059	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura	1	14/11/2015	Open	Y	Study recruited to time and target.
14/EM/1060	A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura	1	30/09/2016	Open	N/A	Date agreed to recruit to target not yet passed.
14/WM/1202	B0401016: A Phase 1b, Randomized, Double-Blind (Sponsor Open), Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04447943, (...) In Subjects With Stable Sickle Cell Disease	5		Open	N/A	No date agreed with sponsor. Study recruited 1 patient to date.
14/LO/1834	A Phase I randomised, placebo-controlled, double-blind, single and multiple ascending dose study of the tolerability and pharmacokinetics of GBT440 in healthy subjects and patients with Sickle Cell Disease	4	24/07/2015	Open	Y	Study recruited to time and target.
15/WM/0009	A Phase 3, Randomised, Controlled, Openlabel Study of VELCADE (Bortezomib MelphalanPrednisone (VMP) Compared to Daratumumab in Combination with VMP (DVMP) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for Highdose Therapy	5	01/11/2021	Open	N/A	Date agreed to recruit to target not yet passed.
15/LO/0210	An exploratory, open-label, multicenter study to evaluate the safety and efficacy of ATIR, donor T-lymphocytes depleted ex vivo of host alloreactive T-cells, in patients with a hematologic malignancy, who received a CD34-selected (...) cell	1	15/07/2017	Closed - In Follow Up	Y	Study recruited to time and target.
15/LO/1105	A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor	3	19/09/2016	Open	N/A	Date agreed to recruit to target not yet passed.
15/LO/0863	AG348-C-003: A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients with Pyruvate Kinase Deficiency.	5	18/08/2017	Open	N/A	Date agreed to recruit to target not yet passed.
15/LO/1087	An Open-label, Multi-centre Post-marketing Study to Assess the Efficacy and Safety of Voncento? in Subjects with Von Willebrand Disease	5	14/10/2016	Open	N/A	Date agreed to recruit to target not yet passed.
10/H0713/35	An International, multi-center, randomized, controlled trial evaluating the effect of xenon on post-operative delirium in elderly patients undergoing hip fracture surgery	6	31/10/2014	Closed - In Follow Up	Y	Study recruited to time and target.
11/EM/0074	A 2-Year, multicenter, double-masked, randomised, parallel study of the safety of LUMIGAN 0.1 mg/mL compared with LUMIGAN 0.3 mg/mL in patients with glaucoma or ocular hypertension	15	30/09/2014	Closed - In Follow Up	Y	Study recruited to time and target.
13/EM/0348	Safety and Efficacy assessment of Monoprost? (unpreserved latanoprost) in comparison with Lumigan? 0.01 % and Lumigan? 0.03% UD, in patients with primary open angle glaucoma or ocular hypertension, stabilized by Lumigan? 0.01 % with ocular surfac	6	31/08/2015	Closed - In Follow Up	Y	Study recruited to time and target.

14/SC/0262	A Phase IV, prospective, open-label, uncontrolled, European Study in patients with neovascular Age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching From intravitreal Aflibercept to Ranibizumab 0.5mg: SAFARI study	6	30/10/2016	Open	N/A	Date agreed to recruit to target not yet passed.
11/EE/0256	Multi-centre, open label, prospective, consecutive series registry database of BioPoly RS Partial Resurfacing Knee implant	10	31/12/2016	Open	N/A	Date agreed to recruit to target not yet passed.
12/NW/0137	A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin	5	03/11/2017	Closed - In Follow Up	Y	Study recruited to time and target.
13/WA/0064	A performance evaluation study of UROSENS Mcm5 ELISA test in the diagnosis of bladder cancer in patients presenting with haematuria and lower urinary tract symptoms with suspicion of malignancy	250	15/01/2014	Closed - In Follow Up	N	Target of 250 patients reached within 10 months.
15/WS/0037	A single-arm, post-market study of the Endo GI Reinforced Reload with Tri-Staple Technology	30	01/05/2016	Open	N/A	Date agreed to recruit to target not yet passed.
11/SC/0454	A phase IIb parallel group, open label study of pegylated interferon alfa-2a monotherapy (PEG-IFN, RO 25-8310) compared to untreated control in children with HBeAg positive chronic hepatitis B	2	01/11/2014	Closed - In Follow Up	Y	Study recruited to time and target.
13/LO/1814	A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of Pergoveris? (follitropin alfa and lutropin alfa) and GONAL-f? (follitropin alfa)			Closed - In Follow Up	N/A	No target/date agreed with sponsor. Study recruited 4 patients.
13/LO/1323	The efficacy and safety of Ferriprox for the treatment of transfusional iron overload in patients with sickle cell disease or other anaemias	5	31/12/2014	Open	N	Study team has confirmed that of the 5 patients with ITP seen during the recruitment period, 2 failed screening. This resulted in the target number (5) being missed. In addition, due to SIV and IMP delivery delays, the time to recruit had been reduced.
14/NW/1506	BlueWind system safety and performance in treatment of patients diagnosed with overactive bladder (OAB)	4		Closed - In Follow Up	Y	Study recruited 11/4 patients.
14/NW/1354	Romiplostim in Thrombocytopenic Paediatric Patients with ITP	5	28/02/2017	Open	N/A	Date agreed to recruit to target not yet passed.
14/LO/2196	A phase 2, double-blind, parallel group, randomised, placebo controlled, proof of concept study to assess the safety and efficacy of OBE001 after oral administration in pregnant women with threatened preterm labour	7		Open	N/A	No date agreed. Study still recruiting. Very restrictive eligibility criteria has been reason for study not being able to recruit patients - in particular the gestational week being very late at 35wks. The CRO was considering dropping down to include 32 wks. Not sites in the UK had recruited; only 2 patients had been recruited globally. Site actively screened 60 patients who were all ineligible.
13/NW/0778	A double-blind, randomised, placebo-controlled, Phase II study to evaluate ProCervix efficacy to clear HPV 16 and HPV 18 infection in women with normal cytology or ASCUS/LSIL	1	30/11/2014	Closed - In Follow Up	Y	Study recruited to time and target.
14/NW/0130	A randomised, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL)	20	01/06/2015	Closed - In Follow Up	Y	Study recruited to time and target.